Ferrara L A, Marotta T, Scilla A, Mastranzo P, Strazzullo P, Mancini M
Eur J Clin Pharmacol. 1984;26(3):331-4. doi: 10.1007/BF00548763.
The aim of the present study was to evaluate whether a reduction in HDL-cholesterol is peculiar to non cardioselective beta blockers or whether it is also produced by cardioselective beta 1-blockers. 16 patients with primary arterial hypertension on a balanced isocaloric diet were given oxprenolol 120 to 240 mg/day or metoprolol 100 to 200 mg/day in a random cross-over study. No significant change was observed after either treatment in fasting blood glucose, serum total cholesterol and triglycerides. HDL-cholesterol concentration was significantly decreased on metoprolol, from 41 to 36 mg/dl (p less than 0.05), while oxprenolol did not affect it at all. The difference might depend on intrinsic sympathomimetic activity which is possessed by oxprenolol and which metoprolol lacks.
本研究的目的是评估高密度脂蛋白胆固醇的降低是否是非心脏选择性β受体阻滞剂所特有的,还是也由心脏选择性β1受体阻滞剂引起。在一项随机交叉研究中,16名原发性动脉高血压患者在均衡等热量饮食的基础上,每天服用120至240毫克氧烯洛尔或100至200毫克美托洛尔。两种治疗后,空腹血糖、血清总胆固醇和甘油三酯均未观察到显著变化。服用美托洛尔后,高密度脂蛋白胆固醇浓度显著降低,从41毫克/分升降至36毫克/分升(p小于0.05),而氧烯洛尔对其完全没有影响。这种差异可能取决于氧烯洛尔所具有而美托洛尔所缺乏的内在拟交感神经活性。